NCI-2022-09176

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF ORAL MRT-2359 IN PATIENTS WITH MYC-DRIVEN AND OTHER SELECTED SOLID TUMORS INCLUDING LUNG CANCER AND DIFFUSE LARGE B-CELL LYMPHOMA

The "ATTACC" study is a Phase 1b/2 clinical trial investigating combinations of an ATR inhibitor called RP-3500 and PARP inhibitors in patients with specific cancers. The study aims to evaluate the safety and effectiveness of these combinations. By targeting both pathways, researchers hope to achieve enhanced anticancer activity against the selected cancers.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05546268

Clinical Trial Site: Columbia

To see all available clinical trials click here.